Gemcitabine-treated pancreatic cancer cell medium induces the specific CTL antitumor activity by stimulating the maturation of dendritic cells

This publication has 32 references indexed in Scilit:

• hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes
  Cancer Immunology, Immunotherapy, 2011
• Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group–Directed Intergroup Trial S0205
  Journal of Clinical Oncology, 2010
• Dendritic Cell‐Based Immunotherapy for Prostate Cancer
  Journal of Immunology Research, 2010
• A Heat Shock Protein 70-Based Vaccine with Enhanced Immunogenicity for Clinical Use
  The Journal of Immunology, 2009
• Epidemiology of pancreatic cancer: an overview
  Nature Reviews Gastroenterology & Hepatology, 2009
• Classification of Chemotherapeutic Agents Based on Their DifferentialIn vitroEffects on Dendritic Cells
  Cancer Research, 2009
• Phase III, Randomized Study of Gemcitabine and Oxaliplatin Versus Gemcitabine (fixed-dose rate infusion) Compared With Gemcitabine (30-minute infusion) in Patients With Pancreatic Carcinoma E6201: A Trial of the Eastern Cooperative Oncology Group
  Journal of Clinical Oncology, 2009
• Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrations
  Journal of Translational Medicine, 2009
• Dendritic cell-based vaccination combined with gemcitabine increases survival in a murine pancreatic carcinoma model
  Gut, 2007
• Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death
  Journal of Experimental Medicine, 2005